The University of Chicago Medical Center /ID# 255674

Chicago, Illinois 60637-1443

1 studies enrolling now · 1 studies all time

What they study most

Hepatocellular Carcinoma

Studies at this site

• A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) — Recruiting now